NeuroMetrix, Inc. (NURO)
| Market Cap | 23.10M |
| Revenue (ttm) | 8.40M |
| Net Income (ttm) | -3.18M |
| Shares Out | 7.13M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,229 |
| Open | 3.27 |
| Previous Close | 3.38 |
| Day's Range | 3.18 - 3.31 |
| 52-Week Range | 2.70 - 38.75 |
| Beta | 2.85 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Apr 26, 2022 |
About NURO
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance...
Financial Performance
In 2021, NeuroMetrix's revenue was $8.25 million, an increase of 11.87% compared to the previous year's $7.38 million. Losses were -$2.28 million, 9.05% more than in 2020.
Financial StatementsNews
NeuroMetrix Reports Q1 2022 Financial Results
WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to redu...
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on Apr...
NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome
NeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Que...
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-lik...
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mi...
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the...
Neurometrix up 35% after receiving FDA Breakthrough Designation for its Quell tech
NeuroMetrix Inc. (NASDAQ: NURO) shot up 35% after announcing that the FDA awarded it Breakthrough Device Designation for its Quell technology. This innovative technology is designed to help reduce sever...
NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today
NeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices. The post NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain ...
NeuroMetrix Shares Rally On FDA Breakthrough Tag For Neurostimulation Device
The FDA has granted Breakthrough Designation to NeuroMetrix Inc's (NASDAQ:NURO) Quell technology for reducing moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have p...
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neu...
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug Administrat...
Best Penny Stocks To Buy Now? 4 On Webull With Bullish User Ratings
Webull penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Brandi Damkier as Vice President, Clinical Partnerships. Ms. Damkier will be respo...
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
WOBURN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the H.C. W...
NeuroMetrix Reports Q3 2021 Financial Results
WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in pr...
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & ...
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. ...
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on Octo...
Why Are NeuroMetrix Shares Shining In Thursday Premarket?
NeuroMetrix Inc (NASDAQ: NURO) submitted a De Novo request to the FDA for Quell as a prescription treatment for fibromyalgia symptoms in adults. The Company received FDA Breakthrough Designation for th...
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearab...
WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a pr...
NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner
WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.
These two stocks gained 30% and 80% on Friday: here's why
The stock market is usually not very exciting on the last day of the week. But some stocks still tend to stir things up a little bit.
What's Going On With NeuroMetrix Shares Today?
NeuroMetrix Inc (NASDAQ: NURO) shares are surging higher Friday on abnormally high volume amid an increase in retail investor interest around the low-float stock. The average session volume is just unde...
NuroMetrix Pushes Higher Friday: What's Next?
NuroMetrix Inc. (NASDAQ:NURO) shares are trading higher Friday after the company began seeing increased retail interest in the stock. The stock has been seeing above average volume the past couple of da...
NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Investors Send Shares Soaring
NeuroMetrix (NURO) is rocketing higher on Friday as retail investors short-squeeze share of the medical device company's stock. The post NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Inve...
NeuroMetrix May Struggle to Stay at Double-Digit Prices
NURO stock is an interesting opportunity for sure. But it may be best to wait for it to head back to single-digit prices before buying.
NueroMetrix Stock Looks Strong Following Its Positive Catalysts
NURO stock received attention from Reddit, but it should interest investors because of its other positive characteristics. The post NueroMetrix Stock Looks Strong Following Its Positive Catalysts appear...